Overview

pharmasol Acquired by PharmaLex to Offer Turnkey End-to-End Pharmacovigilance Solutions.

Significance

Decentralization of clinical trials has accelerated due to increasingly specialized trial designs and trial disruptions caused by COVID 19. The execution of these trials often requires pharmaceutical sponsors and contract research organizations (CROs) to utilize a multitude of vendors in order to ensure effective pharmacovigilance and regulatory compliance. This complexity is driving increased need for end-to-end pharmacovigilance solutions, holistic regulatory strategies, and harmonization of data interoperability.

pharmasol is a leading global life sciences services organization providing tech-enabled pharmacovigilance solutions. The company was one of the last remaining independent providers of automated safety letter distributors in the market. pharmasol’s pharmacovigilance solutions provide automated data management, warehousing, and reporting, making their technology the perfect complement to PharmaLex, one of the leading pharmacovigilance consultancies in the world and a key opinion leader and subject matter expert in pharmacovigilance and safety.

Crosstree’s Role

Crosstree acted as exclusive financial advisor to pharmasol in its acquisition by PharmaLex through:

• Evaluating a broad slate of potential strategic partners in both technology and regulatory spaces to find the optimal fit
• Developing a creative deal structure in which pharmasol gained both the economic upside of a private equity transaction and the synergistic benefits of a strategic partnership
• Leveraging global market expertise to identify the ideal partner; both parties are based in Germany